Company Description
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally.
It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED).
It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease.
The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction.
Petros Pharmaceuticals, Inc. is based in New York, New York.
| Country | United States |
| Founded | 2020 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 21 |
| CEO | John David Shulman |
Contact Details
Address: 1185 Avenue Of The Americas, 3rd Floor New York, New York 10036 United States | |
| Phone | (973) 242-0005 |
| Website | petrospharma.com |
Stock Details
| Ticker Symbol | PTPI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001513856 |
| CUSIP Number | 71678J100 |
| ISIN Number | US71678J2096 |
| Employer ID | 46-3522381 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| John David Shulman | Executive Chairman of the Board |
| Fady Boctor M.B.A. | President and Chief Commercial Officer |
| Mitchell S. Arnold M.B.A. | Vice President of Finance and Chief Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 29, 2021 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Dec 7, 2020 | 8-K | Current Report |
| Dec 2, 2020 | 25-NSE | Filing |
| Nov 25, 2020 | 8-K | Current Report |
| Nov 24, 2020 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 24, 2020 | 8-K | Current Report |
| Nov 20, 2020 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 20, 2020 | 8-K | Current Report |
| Nov 9, 2020 | 10-Q | Quarterly Report |
| Nov 2, 2020 | DEFM14A | Filing |